SG11201704543XA - Bacteria engineered to treat diseases associated with hyperammonemia - Google Patents
Bacteria engineered to treat diseases associated with hyperammonemiaInfo
- Publication number
- SG11201704543XA SG11201704543XA SG11201704543XA SG11201704543XA SG11201704543XA SG 11201704543X A SG11201704543X A SG 11201704543XA SG 11201704543X A SG11201704543X A SG 11201704543XA SG 11201704543X A SG11201704543X A SG 11201704543XA SG 11201704543X A SG11201704543X A SG 11201704543XA
- Authority
- SG
- Singapore
- Prior art keywords
- hyperammonemia
- diseases associated
- treat diseases
- bacteria engineered
- engineered
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/10—Citrulline; Arginine; Ornithine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01001—Amino-acid N-acetyltransferase (2.3.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Oncology (AREA)
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462087854P | 2014-12-05 | 2014-12-05 | |
US201562103513P | 2015-01-14 | 2015-01-14 | |
US201562150508P | 2015-04-21 | 2015-04-21 | |
US201562173706P | 2015-06-10 | 2015-06-10 | |
US201562173710P | 2015-06-10 | 2015-06-10 | |
US201562183935P | 2015-06-24 | 2015-06-24 | |
US201562184811P | 2015-06-25 | 2015-06-25 | |
US201562256039P | 2015-11-16 | 2015-11-16 | |
US201562256041P | 2015-11-16 | 2015-11-16 | |
US201562263329P | 2015-12-04 | 2015-12-04 | |
PCT/US2015/064140 WO2016090343A1 (en) | 2014-12-05 | 2015-12-04 | Bacteria engineered to treat diseases associated with hyperammonemia |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201704543XA true SG11201704543XA (en) | 2017-07-28 |
Family
ID=55022714
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201704543XA SG11201704543XA (en) | 2014-12-05 | 2015-12-04 | Bacteria engineered to treat diseases associated with hyperammonemia |
SG10202010444UA SG10202010444UA (en) | 2014-12-05 | 2015-12-04 | Bacteria engineered to treat diseases associated with hyperammonemia |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202010444UA SG10202010444UA (en) | 2014-12-05 | 2015-12-04 | Bacteria engineered to treat diseases associated with hyperammonemia |
Country Status (10)
Country | Link |
---|---|
US (1) | US9487764B2 (pt) |
JP (1) | JP6768689B2 (pt) |
KR (1) | KR102493174B1 (pt) |
AU (1) | AU2015357549B2 (pt) |
BR (1) | BR112017011923A2 (pt) |
CA (1) | CA2969724A1 (pt) |
IL (2) | IL252627B (pt) |
MX (2) | MX2017007148A (pt) |
SG (2) | SG11201704543XA (pt) |
WO (1) | WO2016090343A1 (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017011923A2 (pt) * | 2014-12-05 | 2018-02-27 | Synlogic Inc | bactéria modificada para tratar doenças associadas com hiperamonemia |
US9688967B2 (en) | 2014-12-05 | 2017-06-27 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
WO2016183531A1 (en) | 2015-05-13 | 2016-11-17 | Synlogic, Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
US20160206666A1 (en) * | 2014-12-22 | 2016-07-21 | Synlogic, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier |
US11883439B2 (en) | 2015-05-13 | 2024-01-30 | Synlogic Operating Company, Inc. | Bacteria engineered to treat a disease or disorder |
WO2016210384A2 (en) * | 2015-06-25 | 2016-12-29 | Synlogic, Inc. | Bacteria engineered to treat metabolic diseases |
US11685925B2 (en) | 2015-10-30 | 2023-06-27 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier |
WO2017123675A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
WO2017139708A1 (en) | 2016-02-10 | 2017-08-17 | Synlogic, Inc. | Bacteria engineered to treat nonalcoholic steatohepatitis (nash) |
WO2017184565A1 (en) | 2016-04-20 | 2017-10-26 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for nucleic acid expression and protein secretion in bacteroides |
WO2018112194A1 (en) | 2016-12-15 | 2018-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating growth of a genetically modified gut bacterial cell |
AU2018205276A1 (en) | 2017-01-06 | 2019-07-18 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
CN110709093A (zh) * | 2017-04-17 | 2020-01-17 | 加利福尼亚大学董事会 | 工程化细菌和使用方法 |
WO2018237198A1 (en) | 2017-06-21 | 2018-12-27 | Synlogic Operating Company, Inc. | BACTERIA FOR THE TREATMENT OF DISORDERS |
EP3648769A4 (en) * | 2017-06-30 | 2021-04-07 | The Rockefeller University | N-ACYL AMIDES DERIVED FROM THE HUMAN MICROBIOTE FOR THE TREATMENT OF HUMAN DISEASE |
US20200149053A1 (en) | 2017-07-12 | 2020-05-14 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
EP3703705B1 (en) | 2017-11-03 | 2024-05-15 | DSM Nutritional Products, LLC | Glucose-containing glycan preparations for use in the treatment of hyperammonaemia |
MX2020005875A (es) * | 2017-12-05 | 2020-10-08 | Bioplx Inc | Métodos y composiciones para prevenir la infección microbiana. |
EP3723775A4 (en) | 2017-12-15 | 2022-04-13 | Solarea Bio, Inc. | MICROBIAL COMPOSITIONS AND METHODS OF TREATMENT OF TYPE 2 DIABETES, OBESITY AND METABOLIC SYNDROME |
AU2019278994A1 (en) | 2018-06-02 | 2020-12-24 | Synlogic Operating Company, Inc. | Bacteria engineered to treat liver disease |
WO2020041531A2 (en) | 2018-08-21 | 2020-02-27 | Kaleido Biosciences, Inc. | Oligosaccharide compositions and methods of use thereof for reducing ammonia levels |
CA3111795A1 (en) | 2018-09-05 | 2020-03-12 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases |
US11980647B2 (en) | 2018-09-05 | 2024-05-14 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
CA3118909A1 (en) | 2018-11-08 | 2020-05-14 | Kaleido Biosciences, Inc. | Oligosaccharide compositions and methods of use thereof |
WO2020223345A1 (en) | 2019-04-29 | 2020-11-05 | Antipov Eugene | Enumeration of genetically engineered microorganisms by live cell counting techniques |
WO2020237246A1 (en) * | 2019-05-23 | 2020-11-26 | University Of Maryland, Baltimore | Live attenuated non-transmissible vaccines |
AU2020288624A1 (en) | 2019-06-04 | 2022-02-03 | Cocoon Biotech Inc. | Silk-based products, formulations, and methods of use |
CN115279888B (zh) | 2019-11-29 | 2024-04-02 | 株式会社Jinis | 具有降低血氨数值效能的菌株及包含其的用于保护神经细胞的组合物 |
CN112924607A (zh) * | 2019-12-05 | 2021-06-08 | 湖北远大生物技术有限公司 | 一种同时检测酶促反应液中α-酮戊二酸和L-谷氨酸的方法 |
EP4121525A1 (en) | 2020-03-20 | 2023-01-25 | Synlogic Operating Company, Inc. | Microorganisms engineered to reduce hyperphenylalaninemia |
WO2022120028A2 (en) | 2020-12-02 | 2022-06-09 | Synlogic Operating Company, Inc. | Engineered microorganisms |
WO2023092150A1 (en) | 2021-11-22 | 2023-05-25 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
US6203797B1 (en) | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
EP1135461A4 (en) | 1998-12-02 | 2003-03-26 | Univ Boston | GENE NETWORKS FOR CONTROLLING GENE EXPRESSION |
EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
JP4682454B2 (ja) * | 2000-06-28 | 2011-05-11 | 味の素株式会社 | 新規変異型n−アセチルグルタミン酸合成酵素及びl−アルギニンの製造法 |
US7731976B2 (en) | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
BR112017011923A2 (pt) * | 2014-12-05 | 2018-02-27 | Synlogic Inc | bactéria modificada para tratar doenças associadas com hiperamonemia |
-
2015
- 2015-12-04 BR BR112017011923A patent/BR112017011923A2/pt not_active Application Discontinuation
- 2015-12-04 US US14/960,333 patent/US9487764B2/en active Active
- 2015-12-04 MX MX2017007148A patent/MX2017007148A/es unknown
- 2015-12-04 KR KR1020177018338A patent/KR102493174B1/ko active IP Right Grant
- 2015-12-04 JP JP2017548375A patent/JP6768689B2/ja active Active
- 2015-12-04 WO PCT/US2015/064140 patent/WO2016090343A1/en active Application Filing
- 2015-12-04 CA CA2969724A patent/CA2969724A1/en not_active Abandoned
- 2015-12-04 AU AU2015357549A patent/AU2015357549B2/en not_active Ceased
- 2015-12-04 SG SG11201704543XA patent/SG11201704543XA/en unknown
- 2015-12-04 SG SG10202010444UA patent/SG10202010444UA/en unknown
-
2017
- 2017-06-01 IL IL252627A patent/IL252627B/en active IP Right Grant
- 2017-06-05 MX MX2021006581A patent/MX2021006581A/es unknown
-
2020
- 2020-10-19 IL IL278150A patent/IL278150A/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG10202010444UA (en) | 2020-11-27 |
WO2016090343A9 (en) | 2016-09-09 |
KR102493174B1 (ko) | 2023-01-27 |
MX2017007148A (es) | 2017-10-11 |
KR20170097078A (ko) | 2017-08-25 |
AU2015357549B2 (en) | 2022-03-24 |
IL278150A (en) | 2020-11-30 |
BR112017011923A2 (pt) | 2018-02-27 |
WO2016090343A1 (en) | 2016-06-09 |
JP2018504919A (ja) | 2018-02-22 |
CA2969724A1 (en) | 2016-06-09 |
IL252627A0 (en) | 2017-07-31 |
IL252627B (en) | 2020-11-30 |
JP6768689B2 (ja) | 2020-10-14 |
AU2015357549A1 (en) | 2017-06-29 |
US20160177274A1 (en) | 2016-06-23 |
MX2021006581A (es) | 2021-07-15 |
US9487764B2 (en) | 2016-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL278150A (en) | A transgenic bacterium for the treatment of diseases related to hyperammonemia | |
ZA201707678B (en) | Bacteria engineered to reduce hyperphenylalaninemia | |
SG11201701585VA (en) | Mutant microorganisms resistant to lactose killing | |
IL248856B (en) | New treatment | |
PL3377518T3 (pl) | Bakterie modyfikowane do celów zmniejszenia hiperfenyloalaninemii | |
GB201413333D0 (en) | Plant inoculation | |
GB201401430D0 (en) | Treatment process | |
GB201408039D0 (en) | Culture dish | |
GB2531635B (en) | Water treatment | |
ZA201608406B (en) | Enzyme treatment composition | |
EP3114232A4 (en) | Chimeric dystrophin-vsv-g-protein to treat dystrophinopathies | |
GB201411027D0 (en) | Treatment | |
ZA201608404B (en) | Enzyme treatment composition | |
GB201413330D0 (en) | Agricultural treatment | |
GB201400839D0 (en) | Agricultural treatment | |
GB201421889D0 (en) | Improvements in or relating to effluent treatment | |
GB201400377D0 (en) | Methods relating to wool treatment | |
GB201419842D0 (en) | Psoriasis treatment fish tank | |
GB201410990D0 (en) | General cure to diseases | |
GB201413535D0 (en) | Culture | |
AU2014903957A0 (en) | Water treatment methods | |
GB201413317D0 (en) | Atheroscierosis treatment | |
GB201417719D0 (en) | New treatment | |
GB201412411D0 (en) | Treatment | |
GB201412410D0 (en) | Treatment |